StocksMedium•8 October 2026•
1 min read
AbbVie Stock Edges Higher as FDA Grants Breakthrough Status to Cancer Drug
Key Facts
1AbbVie Inc. shares rose 0.44% after hours following FDA breakthrough designations for telisotuzumab adizutecan in two cancers.
AbbVie Inc. shares rose 0.44% in after-hours trading following the FDA's decision to grant breakthrough therapy designations to its drug telisotuzumab adizutecan. Benzinga reported that the designation applies to two specific cancer types and is designed to expedite the development and review process for treatments targeting serious conditions.
ABBV closed at $271.36 on October 7, 2026, with a session high of $274.94 and a low of $266.89. The modest uptick reflects investor reaction to the drug's clinical potential, which signals a positive catalyst for the company's oncology pipeline development.